Coward, SM; Mavri-Damelin, D; Hodgson, HJ; Selden, C; Legallais, C; David, B; ... Foo, Y; + view all Coward, SM; Mavri-Damelin, D; Hodgson, HJ; Selden, C; Legallais, C; David, B; Thomas, M; Foo, Y; - view fewer (2009) Alginate-encapsulated HepG2 cells in a fluidized bed bioreactor maintain function in human liver failure plasma. Artificial Organs , 33 (12) 1117 - 1126. 10.1111/j.1525-1594.2009.00821.x.
Full text not available from this repository.
Alginate-encapsulated HepG2 cells cultured in microgravity have the potential to serve as the cellular component of a bioartificial liver. This study investigates their performance in normal and liver failure (LF) human plasma over 6-8 h in a fluidized bed bioreactor. After 8 days of microgravity culture, beads containing 1.5 × 10 cells were perfused for up to 8 h at 48 mL/min with 300 mL of plasma. After exposure to 90% LF plasma, vital dye staining showed maintained cell viability, while a 7% increase in lactate dehydrogenase activity indicated minimal cell damage. Glucose consumption, lactate production, and a 4.3-fold linear increase in alpha-fetoprotein levels were observed. Detoxificatory function was demonstrated by quantification of bilirubin conjugation, urea synthesis, and Cyp450 1A activity. These data show that in LF plasma, alginate-encapsulated HepG2 cells can maintain viability, and metabolic, synthetic, and detoxificatory activities, indicating that the system can be scaled-up to form the biological component of a bioartificial liver. © 2009, International Center for Artificial Organs and Transplantation and Wiley Periodicals, Inc.
|Title:||Alginate-encapsulated HepG2 cells in a fluidized bed bioreactor maintain function in human liver failure plasma|
Archive Staff Only: edit this record